Artesunate, an anti-malarial drug, has a potential to inhibit HCV replication

详细信息    查看全文

• 作者：Rongjuan Dai ; Xinqiang Xiao ; Feng Peng ; Mingming Li ; Guozhong Gong
• 关键词：Hepatitis C virus ; Antiviral ; Artesunate ; Ribavirin ; Interferon
• 刊名：Virus Genes
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：52
• 期：1
• 页码：22-28
• 全文大小：872 KB
• 参考文献：1.D.L. Thomas, Nat. Med. 19, 850–858 (2013)CrossRef PubMed
  2.A. Craxi, A. Licata, Semin. Liver Dis. 23(Suppl 1), 35–46 (2003)PubMed
  3.M.G. Ghany, D.R. Nelson, D.B. Strader, D.L. Thomas, L.B. Seeff, Hepatology 54, 1433–1444 (2011)PubMedCentral CrossRef PubMed
  4.H.W. Reesink, S. Zeuzem, C.J. Weegink, N. Forestier, A. van Vliet, D.R.J. van de Wetering, L. McNair, S. Purdy, R. Kauffman, J. Alam, P.L. Jansen, Gastroenterology 131, 997–1002 (2006)CrossRef PubMed
  5.J.M. Pawlotsky, Hepatology 53, 1742–1751 (2011)CrossRef PubMed
  6.N.J. White, Science 320, 330–334 (2008)CrossRef PubMed
  7.M. Adjuik, A. Babiker, P. Garner, P. Olliaro, W. Taylor, N. White, Lancet 363, 9–17 (2004)CrossRef PubMed
  8.X. Zhou, W.J. Sun, W.M. Wang, K. Chen, J.H. Zheng, M.D. Lu, P.H. Li, Z.Q. Zheng, Anticancer Drugs 24, 920–927 (2013)CrossRef PubMed
  9.K.T. Batty, T.M. Davis, L.T. Thu, T.Q. Binh, T.K. Anh, K.F. Ilett, J. Chromatogr. B Biomed. Appl. 677, 345–350 (1996)CrossRef PubMed
  10.W. Jiang, B. Li, X. Zheng, X. Liu, X. Pan, R. Qing, Y. Cen, J. Zheng, H. Zhou, J. Antibiot. 66, 339–345 (2013)CrossRef PubMed
  11.P.M. O’Neill, G.H. Posner, J. Med. Chem. 47, 2945–2964 (2004)CrossRef PubMed
  12.T. Efferth, M.R. Romero, D.G. Wolf, T. Stamminger, J.J. Marin, M. Marschall, Clin. Infect. Dis. 47, 804–811 (2008)CrossRef PubMed
  13.R. Arav-Boger, R. He, C.J. Chiou, J. Liu, L. Woodard, A. Rosenthal, L. Jones-Brando, M. Forman, G. Posner, PLoS One 5, e10370 (2010)PubMedCentral CrossRef PubMed
  14.R. He, B.T. Mott, A.S. Rosenthal, D.T. Genna, G.H. Posner, R. Arav-Boger, PLoS One 6, e24334 (2011)PubMedCentral CrossRef PubMed
  15.M.R. Romero, T. Efferth, M.A. Serrano, B. Castano, R.I. Macias, O. Briz, J.J. Marin, Antiviral Res. 68, 75–83 (2005)CrossRef PubMed
  16.K.J. Blight, J.A. McKeating, C.M. Rice, J. Virol. 76, 13001–13014 (2002)PubMedCentral CrossRef PubMed
  17.V. Lohmann, F. Korner, J. Koch, U. Herian, L. Theilmann, R. Bartenschlager, Science 285, 110–113 (1999)CrossRef PubMed
  18.L.D. Presser, A. Haskett, G. Waris, Virology 412, 284–296 (2011)PubMedCentral CrossRef PubMed
  19.M. Ikeda, K. Abe, H. Dansako, T. Nakamura, K. Naka, N. Kato, Biochem. Biophys. Res. Commun. 329, 1350–1359 (2005)CrossRef PubMed
  20.J. Paeshuyse, L. Coelmont, I. Vliegen, J. Van Hemel, J. Vandenkerckhove, E. Peys, B. Sas, E. De Clercq, J. Neyts, Biochem. Biophys. Res. Commun. 348, 139–144 (2006)CrossRef PubMed
  21.R.S. Miller, Q. Li, L.R. Cantilena, K.J. Leary, G.A. Saviolakis, V. Melendez, B. Smith, P.J. Weina, Malar J. 11, 255 (2012)PubMedCentral CrossRef PubMed
  22.R. Price, M. van Vugt, L. Phaipun, C. Luxemburger, J. Simpson, R. McGready, F. ter Kuile, A. Kham, T. Chongsuphajaisiddhi, N.J. White, F. Nosten, Am. J. Trop. Med. Hyg. 60, 547–555 (1999)PubMed
  23.T. Efferth, M. Marschall, X. Wang, S.M. Huong, I. Hauber, A. Olbrich, M. Kronschnabl, T. Stamminger, E.S. Huang, J. Mol. Med. 80, 233–242 (2002)CrossRef PubMed
  24.S.R. Meshnick, Y.Z. Yang, V. Lima, F. Kuypers, S. Kamchonwongpaisan, Y. Yuthavong, Antimicrob. Agents Chemother. 37, 1108–1114 (1993)PubMedCentral CrossRef PubMed
  25.G.H. Posner, C.H. Oh, D. Wang, L. Gerena, W.K. Milhous, S.R. Meshnick, W. Asawamahasadka, J. Med. Chem. 37, 1256–1258 (1994)CrossRef PubMed
  26.J. Choi, K.J. Lee, Y. Zheng, A.K. Yamaga, M.M. Lai, J.H. Ou, Hepatology 39, 81–89 (2004)CrossRef PubMed
  27.T. Zima, M. Kalousova, Alcohol. Clin. Exp. Res. 29, 110S–115S (2005)CrossRef PubMed
  28.D. Burdette, M. Olivarez, G. Waris, J. Gen. Virol. 91, 681–690 (2010)CrossRef PubMed
  29.G. Waris, A. Livolsi, V. Imbert, J.F. Peyron, A. Siddiqui, J. Biol. Chem. 278, 40778–40787 (2003)CrossRef PubMed
  
• 作者单位：Rongjuan Dai (1)
  Xinqiang Xiao (1)
  Feng Peng (1)
  Mingming Li (1)
  Guozhong Gong (1)
  
  1. Department of Infectious Diseases, Second Xiangya Hospital, Central South University, 139 Renmin Zhong Road, Changsha, 410011, Hunan, China
  
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Biomedicine
  Medical Microbiology
  Virology
  Plant Sciences
  
• 出版者：Springer Netherlands
• ISSN：1572-994X

文摘

Hepatitis C virus (HCV) infection is a major global health issue. Although the search for HCV treatments has resulted in great achievements, the current treatment methods have limitations, and new methods and drugs for hepatitis C treatment are still required. The aim of the present study was to investigate the effects of artesunate (ART) on HCV replication and compared these effects with those of ribavirin (RBV) and interferon-2b (IFN). The study was performed in HCV-infection cell models (JFH1-infected Huh7.5.1 and OR6 cell lines). Our results showed that the antimalarial drug ART inhibited HCV replicon replication in a dose- and time-dependent manner at a concentration that had no effect on the proliferation of exponentially growing host cells, and the inhibitory effect on HCV replication was stronger than RBV but weaker than IFN, as determined by qPCR, luciferase assays, and Western blot analysis. Furthermore, the combination of ART and IFN resulted in a greater inhibition of HCV replication. These findings demonstrated that ART had an inhibitive effect on HCV replication and may be a novel supplemental co-therapy with IFN and RBV for HCV and as an alternative strategy to combat resistance mechanisms that have emerged in the presence of DAA agents. Keywords Hepatitis C virus Antiviral Artesunate Ribavirin Interferon